Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Major Shareholder Brightstar Associates Llc Acquires 1,666,666 Shares

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) major shareholder Brightstar Associates Llc bought 1,666,666 shares of Deciphera Pharmaceuticals stock in a transaction dated Tuesday, January 24th. The shares were bought at an average cost of $18.00 per share, with a total value of $29,999,988.00. Following the completion of the acquisition, the insider now owns 19,718,014 shares of the company’s stock, valued at $354,924,252. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Deciphera Pharmaceuticals Price Performance

Shares of DCPH stock opened at $18.05 on Wednesday. Deciphera Pharmaceuticals, Inc. has a fifty-two week low of $6.51 and a fifty-two week high of $22.76. The stock’s 50-day moving average is $17.03 and its two-hundred day moving average is $16.53. The firm has a market cap of $1.22 billion, a P/E ratio of -5.22 and a beta of 0.73.

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.02. The company had revenue of $35.97 million for the quarter, compared to analyst estimates of $33.29 million. Deciphera Pharmaceuticals had a negative return on equity of 63.88% and a negative net margin of 177.53%. As a group, research analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.5 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on DCPH. SVB Leerink upped their target price on Deciphera Pharmaceuticals from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, January 4th. Stifel Nicolaus increased their price objective on Deciphera Pharmaceuticals from $11.00 to $18.00 and gave the stock a “hold” rating in a research note on Tuesday, September 27th. Jonestrading raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 6th. Barclays increased their price objective on Deciphera Pharmaceuticals from $8.00 to $9.00 and gave the stock an “underweight” rating in a research note on Wednesday, January 4th. Finally, Guggenheim raised Deciphera Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Wednesday, January 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Deciphera Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $21.44.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Great West Life Assurance Co. Can acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter valued at about $43,000. US Bancorp DE increased its holdings in shares of Deciphera Pharmaceuticals by 100.6% during the 2nd quarter. US Bancorp DE now owns 4,052 shares of the company’s stock valued at $53,000 after acquiring an additional 2,032 shares during the last quarter. Amalgamated Bank acquired a new position in shares of Deciphera Pharmaceuticals during the 1st quarter valued at about $57,000. Lazard Asset Management LLC acquired a new position in shares of Deciphera Pharmaceuticals during the 1st quarter valued at about $57,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter valued at about $124,000. Institutional investors and hedge funds own 72.66% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

(Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.